ADVANCED OR METASTATIC NSCLC
Clinical trials for ADVANCED OR METASTATIC NSCLC explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC NSCLC trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat lung cancer: testing a Two-Drug combo
Disease control OngoingThis study is testing whether a new combination of two drugs, ceralasertib (a pill) and durvalumab (an IV infusion), can help control advanced non-small cell lung cancer. It is for adults whose cancer has continued to grow despite receiving standard immunotherapy and chemotherapy…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Early trial tests promising new combo for Tough-to-Treat lung cancer
Disease control OngoingThis early-stage study is testing the safety of a new drug called datopotamab deruxtecan when combined with immunotherapy, with or without a standard chemotherapy drug, for people with advanced non-small cell lung cancer. The main goal is to find safe dose levels and see how well…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC